FDA Tweaks Patent Delay Petitions for Drugs
Published Date: 5/21/2026
Notice
Summary
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
Estimated Annual Time Burden
FDA estimates annual respondent burden of 560 hours total: five revision requests of regulatory review period determinations at 100 hours each (500 hours), one due diligence petition at 50 hours, and one due diligence hearing request at 10 hours. FDA estimates no capital or operating costs and based these numbers on the average filings over the past 3 years.
Paperwork Rules for Patent Extensions
If you are a patent holder for a new drug, biologic, medical device, animal drug, food additive, or color additive, FDA is continuing the information-collection requirements (OMB control number 0910-0233) for petitions under 21 CFR part 60. The agency submitted this paperwork collection to OMB for review under the Paperwork Reduction Act and is seeking public comment by June 22, 2026.
No Change to 'Due Diligence' Definition
FDA stated it believes the existing definition of "due diligence" in 21 CFR 60.36(a) is adequate and will not revise that definition in this submission. Petitioners should plan under the current definition, which FDA quotes as the degree of attention, continuous directed effort, and timeliness reasonably expected during a regulatory review period.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10188 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice (CGMP): Manufacturing, Processing, Packing, and Holding of Drugs; GMP for Finished Pharmaceuticals (Including Active Pharmaceutical Ingredients) and the Advanced Manufacturing Technologies Designation Program
The FDA is updating how it collects info about drug making to keep medicines safe and high-quality. This affects drug makers who must follow good manufacturing rules and may see some changes in paperwork. Comments on these updates are open until June 22, 2026, so industry folks have time to weigh in before any new rules kick in.
Previous / Next Documents
Previous: 2026-10189 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Adverse Experience/Events With Approved New Animal Drugs
The FDA is asking for approval to keep collecting info about problems with approved new animal drugs, like side effects or manufacturing issues. This helps make sure animal medicines stay safe and effective. Drug companies need to keep reporting these issues, and the public can comment until June 22, 2026. There’s no new cost, just a continuation of current rules.
Next: 2026-10191 — Agency Information Collection Activities; Proposed Information Collection Request; Comment Request; Performance Evaluation Studies on Wastewater Laboratories (Renewal)
The EPA wants to keep checking how well wastewater labs do their tests by renewing a paperwork request that helps them gather info. This affects labs that test water and anyone interested can share their thoughts by July 20, 2026. The renewal keeps things running smoothly without extra costs or big changes, just more time to keep the quality high.